Cat. No.: HY-17566

Capreomycin sulfate

5 Cited Publications

Customer Review

Based on 5 publication(s) in Google Scholar

Capreomycin sulfate is a macrocyclic peptide antibiotic that inhibits phenylalanine synthesis in mycobacterial ribosomal translation. Capreomycin sulfate has anti-amyloidogenic and pro-fibrinolytic activities, reducing amyloid-induced cytotoxicity by inhibiting the occurrence of amyloid fibrillation. Capreomycin sulfate can be used in the study of multidrug-resistant tuberculosis, type 2 diabetes, Alzheimer's disease and Parkinson's disease.

For research use only. We do not sell to patients.

Purity: 99.0%
CAS No.: 1405-37-4

Storage:

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Capreomycin sulfate Chemical Structure

CAS No.: 1405-37-4

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (5)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

Aminoglycoside

All Antibiotic Isoforms :

In Vitro

Capreomycin sulfate (10-200 μM; 80 h) inhibits the formation of insulin fibrils in human erythrocytes in a concentration-dependent manner (IC₅₀=69.98 μM) and has a delayed fibrillation process^[3].
Capreomycin sulfate (75-100 μM; 60 min) shows a dose-dependent protective effect against amyloid fibril-induced erythrocyte damage and hemolysis^[3].
Capreomycin sulfate (100 μM; 0-48 h) effectively destroys fibrils in erythrocytes in a time-dependent manner^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:

human erythrocyte
Concentration:

75 and 100 µM
Incubation Time:

30 min
Result:

The hemolysis rates were 23.8% and 13.0% at 75µM and 100µM, respectively.

In Vivo

Capreomycin sulfate (1.4-14.5 mg/kg for insufflation; 20 mg/kg for i.m., 4 weeks) decreases the wet lung weight and lowers bacterial burden in the lungs of infected guinea pigs^[2].

Pharmacokinetic Analysis in the guinea pig model^[2]

Route	Dose (mg/kg)	AUC_0-t (ng h/mL)	CL_F (mL/h kg)	K (h^-1)	t_1/2 (h)	MRT (h)	C_max (ng/mL)	T_max (h)	MAT (h)	F_0-t
i.v.	20	49.29	0.42	0.92	0.75	0.88	53.36	0.08	/	1.00
i.m.	20	58.2	0.35	0.68	1.09	1.44	32.33	0.36	0.44	1.20
Insufflation	14.5	16.95	0.54	0.48	1.53	1.80	6.70	0.31	0.80	0.54
Insufflation	7.2	8.2	0.52	0.45	1.68	1.72	3.34	0.38	0.72	0.59
Insufflation	1.4	1.15	0.67	0.71	1.22	1.01	0.92	0.5	/	0.41

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male guinea pigs [836 ± 162.3 g; infected via the respiratory route with nebulized suspensions 2 × 105 CFU/mL of Mycobacterium tuberculosis (strain H37Rv)] ^[2]
Dosage:

1.4, 7.2, and 14.5 mg/kg for Insufflation; 20 mg/kg for Intramuscular injection
Administration:

Insufflation or Intramuscular injection; 4 weeks
Result:

Decreased the wet lung weight at 14.5 mg/kg, and smaller than receiving 1.4 mg/kg group and controls.
Lowered bacterial burden in the lungs (3.52 CFU/mL) at 14.5 mg/kg than controls (4.58 CFU/mL) and at 1.4 and 7.2 mg/kg (4.02 and 4.01 CFU/mL, respectively)

Chemical Information

CAS No. 1405-37-4
Appearance Solid
Color White to off-white
SMILES

OS(O)(=O)=O.[R]C[C@H](N1)C(N[C@@H](CNC(CC(N)CCCN)=O)C(N/C(C(N[C@H](C(NC[C@H](N)C1=O)=O)[C@@H]2NC(NCC2)=N)=O)=C\NC(N)=O)=O)=O.OS(O)(=O)=O.[R=OH 1A].[R=H 1B]
Structure Classification
- Antibiotics
- Other Antibiotics
- Antibiotics
- Mammalian Cell Culture
Initial Source
- Microorganisms
Streptomyces capreolus
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (5)

All

Sort by:

Journal Impact Factor

EBioMedicine

Diverse impacts of different rpoB mutations on the anti-tuberculosis efficacy of capreomycin. [Abstract]

2025 May 30:117:105776. PMID: 40449326
mLife

Identification of a phenyl ester covalent inhibitor of caseinolytic protease and analysis of the ClpP1P2 inhibition in mycobacteria. [Abstract]

2025 Apr 15;4(2):155-168. PMID: 40313980
ACS Chem Biol

Investigate Natural Product Indolmycin and the Synthetically Improved Analogue Toward Antimycobacterial Agents. [Abstract]

2022 Jan 21;17(1):39-53. PMID: 34908399
Tuberculosis

The rv2820c K114N mutation is related with capreomycin tolerance. [Abstract]

2024 Jul 26:148:102551. PMID: 39084000
bioRxiv

2025 May 30.

Solvent & Solubility

In Vitro:

H₂O : 100 mg/mL (Need ultrasonic)

View the Complete Stock Solution Preparation Table

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL; Clear solution; Need ultrasonic

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Maus CE, et al. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2005 Feb;49(2):571-7. [Content Brief]

[2]. Garcia-Contreras L, et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother. 2007 Aug;51(8):2830-6. [Content Brief]

[3]. Siddiqi M K, et al. Capreomycin inhibits the initiation of amyloid fibrillation and suppresses amyloid induced cell toxicity[J]. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics, 2018, 1866(4): 549-557. [Content Brief]

[4]. Reisfeld B, et al. A physiologically based pharmacokinetic model for capreomycin[J]. Antimicrobial agents and chemotherapy, 2012, 56(2): 926-934. [Content Brief]

[5]. Le Conte P, et al. Pharmacokinetics, toxicity, and efficacy of liposomal capreomycin in disseminated Mycobacterium avium beige mouse model[J]. Antimicrobial agents and chemotherapy, 1994, 38(12): 2695-2701. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Capreomycin sulfate

5 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Capreomycin sulfate

Anti-Infection Compound Library

Natural Product Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Covalent Screening Library

Anti-diabetic Compound Library

Macrocyclic Compound Library

Antibacterial Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Anti-Alzheimer's Disease Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Microbial Metabolite Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Coagulation and Anti-coagulation Compound Library

Off-patent Drug Library

Anti-tuberculosis Compound Library

Anti-Drug-Resistant Compound Library

Bioactive Compound Library Max

Covalent Screening Library Plus

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Capreomycin sulfate

All Antibiotic Isoforms

Biological Activity

Chemical Information

Publications (5)

Solvent & Solubility

Purity & Documentation

References

Calculators

Help & FAQs

Capreomycin sulfate Related Classifications

HY-17566 Related Classifications